Nutraceutical Potential of Phenolics from `Brava´ and `Mansa´ Extra-Virgin Olive Oils on the Inhibition of Enzymes Associated to Neurodegenerative Disorders in Comparison with Those of `Picual´ and `Cornicabra´
Metadatos
Mostrar el registro completo del ítemAutor
Figueiredo-González, María; Reboredo-Rodríguez, Patricia; González-Barreiro, Carmen; Carrasco Pancorbo, Alegría; Simal-Gándara, Jesús; Cancho-Grande, BeatrizEditorial
MDPI
Materia
Extra-virgin olive oil Cholinesterases Monoamine oxidases Lipoxygenase Phenolic compounds Neurodegenerative disorders Alzheimer´s disease Parkinson´s disease Major depressive disorder
Fecha
2018-03-21Referencia bibliográfica
Figueiredo-González, Mª. [et al.]. Nutraceutical Potential of Phenolics from `Brava´ and `Mansa´ Extra-Virgin Olive Oils on the Inhibition of Enzymes Associated to Neurodegenerative Disorders in Comparison with Those of `Picual´ and `Cornicabra´. Molecules 2018, 23, 722. [http://hdl.handle.net/10481/55389]
Patrocinador
This work received financial support from Programa de Cooperación Interreg V-A España—Portugal (POCTEP) 2014–2020 (projects Ref.: 0181_NANOEATERS_01_E and Ref: 0377_IBERPHENOL_6_E).Resumen
The increasing interest in theMediterranean diet is based on the protective effects against several
diseases, including neurodegenerative disorders. Polyphenol-rich functional foods have been proposed to
be unique supplementary and nutraceutical treatments for these disorders. Extra-virgin olive oils (EVOOs)
obtained from 0Brava0 and 0Mansa0, varieties recently identified from Galicia (northwestern Spain), were
selected for in vitro screening to evaluate their capacity to inhibit key enzymes involved in Alzheimer0s
disease (AD) (acetylcholinesterase (AChE), butyrylcholinesterase (BuChE) and 5-lipoxygenase (5-LOX)),
major depressive disorder (MDD) and Parkinson0s disease (PD) (monoamine oxidases: hMAO-A and
hMAO-B respectively). 0Brava0 oil exhibited the best inhibitory activity against all enzymes, when they
are compared to 0Mansa0 oil: BuChE (IC50 = 245 ± 5 and 591 ± 23 mg.mL-1), 5-LOX (IC50 = 45 ± 7 and
106±14 mg.mL-1), hMAO-A (IC50 = 30 ± 1 and 72 ± 10 mg.mL-1) and hMAO-B (IC50 = 191 ± 8 and
208 ±14 mg.mL-1), respectively. The inhibitory capacity of the phenolic extracts could be associated
with the content of secoiridoids, lignans and phenolic acids.